Skip to main content

Table 1 Patient demographic data

From: Cost-utility analysis of adjuvant goserelin (Zoladex) and adjuvant chemotherapy in premenopausal women with breast cancer

  Adjuvant therapy
  Goserelin Chemotherapy
Age (year) 40.8 ± 6.5 41.9 ± 5.7
Follow-up (month) 168 273
10-year survival rate 0.88 0.82
Life expectancy of patient population (months) 432 ± 23 401 ± 17
Life expectancy of reference population (months) 474 ± 1 467 ± 1
Life time lost (months) 42 66